On August 21, Cofco Biotechnology Co.,Ltd. released its semi-annual report.
According to the announcement, the company recorded operating revenue of 8,812,266,188.03 yuan in the first half, representing a year-over-year decrease of 11.09%. Net profit attributable to shareholders of the listed company reached 107,246,574.11 yuan, marking a significant increase of 74.44% compared to the same period last year.
The announcement also revealed that among the top ten circulating shareholders, Industrial and Commercial Bank of China - GF CSI 1000 Exchange Traded Fund became a new circulating shareholder during the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments